Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development

黄热病、rDNA (EP IL-12) 和 rAd35 作为艾滋病疫苗开发的载体

• 批准号: 8688135
• 负责人: David I Watkins
• 金额: $ 194.7万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8688135
• 关键词: AIDS vaccine development; Acute; Address; Adenoviruses; Animals; Area; Attenuated; Chronic Phase; Clinical Trials; Control Animal; Cytomegalovirus; Data; Dose; Electroporation; Figs - dietary; Gagging; Genes; Genome; HIV; HIV vaccine; Human; Immune response; Immunity; Immunization; Intention; Interleukin-12; Macaca; Macaca mulatta; Methods; Muscle; NIH Program Announcements; Open Reading Frames; Outcome; Phase; Plasmids; Proteins; Proteome; RNA; Recombinant DNA; Recombinant Interleukin-12; Recombinants; Regimen; Research; Role; SIV; Series; Serotyping; T cell response; Testing; Tissues; Vaccinated; Vaccination; Vaccine Design; Vaccines; Viral; Viral Load result; Viremia; Virus; Virus Replication; Work; Yellow Fever; Yellow Fever Vaccine; design; improved; lymph nodes; nonhuman primate; novel vaccines; plasmid DNA; prevent; public health relevance; rectal; research study; vaccine development; vector

DESCRIPTION (provided by applicant): We plan to explore whether the highly successful attenuated yellow fever (YF-17D) vaccine, rDNA delivered by electroporation along with IL-12 and rAd35 can be used as vectors to express SIV proteins in a prime/boost regimen for vaccination against the AIDS virus. In a highly integrated series of experiments, we will first define the best viral targets for a vaccine. We will then bring the results together in a final efficacy experiment to test the vectors that, if successful, could prevent suffering by millions of people worldwide. Our application seeks to address four of the ten research areas outlined in the HIVRAD program announcement. Our project has the potential to impact HIV vaccine development on two fronts. First, we will define the targets of a successful vaccine in a challenge experiment. This will allow us to design a vaccine encoding the critical targets of a successful immune response. Second, we will develop three entirely novel vaccine vectors. If we are successful in this endeavor, our results will have a profound effect on HIV vaccine design.

描述（由申请人提供）：我们计划探索非常成功的减毒黄热病 (YF-17D) 疫苗、通过电穿孔传递的 rDNA 以及 IL-12 和 rAd35 是否可以用作载体，在初免/加强中表达 SIV 蛋白艾滋病病毒疫苗接种方案。在一系列高度集成的实验中，我们将首先确定疫苗的最佳病毒靶标。然后，我们将把结果汇总到最终的功效实验中，以测试这些载体，如果成功，可以避免数百万人遭受痛苦。 世界各地的人们。我们的应用程序旨在解决 HIVRAD 计划公告中概述的十个研究领域中的四个。我们的项目有可能在两个方面影响艾滋病毒疫苗的开发。首先，我们将在挑战实验中确定成功疫苗的目标。这将使我们能够设计一种编码成功免疫反应的关键目标的疫苗。其次，我们将开发三种全新的疫苗载体。如果我们在这一努力中取得成功，我们的结果将对艾滋病毒疫苗的设计产生深远的影响。